Frontiers in pharmacology · 2026
Pretreatment with different doses of oliceridine attenuates etomidate-induced myoclonus during painless gastroscopy: a randomized controlled trial.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Yingchuan, Dai Yun, Huang Weifeng, Zhang Huaijian, Yang Bin
Аннотация
BACKGROUND: Etomidate is commonly used for sedation during gastroscopy but is associated with a high incidence of myoclonus. This study evaluated the effectiveness of oliceridine pretreatment in reducing etomidate-induced myoclonus.
METHODS: In this prospective, double-blind, randomized controlled trial, 150 patients undergoing painless gastroscopy were assigned to receive oliceridine at 0.01 mg/kg (Group A1), 0.02 mg/kg (Group A2), or normal saline (Group S) prior to etomidate administration. Remifentanil (0.2 μg/kg) and etomidate (0.3 mg/kg) were then administered. The incidence and severity of myoclonus were assessed within 60 s post-etomidate injection. Hemodynamic parameters, adverse effects, and satisfaction scores were also evaluated.
RESULTS: The incidence of myoclonus was significantly lower in Groups A1 (28%) and A2 (16%) compared to Group S (58%) (p < 0.001). Severe myoclonus occurred less frequently in the oliceridine groups. Heart rate (HR) at T1 and T2 was significantly lower in Groups A1 and A2 than in Group S (p < 0.05). No significant intergroup differences were observed in mean arterial pressure (MAP) or pulse oxygen saturation (SpO2). Injection pain, hiccups, and cough were less frequent in the oliceridine groups, although not statistically significant.
CONCLUSION: Pretreatment with oliceridine effectively reduces the incidence and severity of etomidate-induced myoclonus during painless gastroscopy without compromising hemodynamic stability.
CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn, identifier ChiCTR2500103005.
METHODS: In this prospective, double-blind, randomized controlled trial, 150 patients undergoing painless gastroscopy were assigned to receive oliceridine at 0.01 mg/kg (Group A1), 0.02 mg/kg (Group A2), or normal saline (Group S) prior to etomidate administration. Remifentanil (0.2 μg/kg) and etomidate (0.3 mg/kg) were then administered. The incidence and severity of myoclonus were assessed within 60 s post-etomidate injection. Hemodynamic parameters, adverse effects, and satisfaction scores were also evaluated.
RESULTS: The incidence of myoclonus was significantly lower in Groups A1 (28%) and A2 (16%) compared to Group S (58%) (p < 0.001). Severe myoclonus occurred less frequently in the oliceridine groups. Heart rate (HR) at T1 and T2 was significantly lower in Groups A1 and A2 than in Group S (p < 0.05). No significant intergroup differences were observed in mean arterial pressure (MAP) or pulse oxygen saturation (SpO2). Injection pain, hiccups, and cough were less frequent in the oliceridine groups, although not statistically significant.
CONCLUSION: Pretreatment with oliceridine effectively reduces the incidence and severity of etomidate-induced myoclonus during painless gastroscopy without compromising hemodynamic stability.
CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn, identifier ChiCTR2500103005.